Solid Neoplasm

This was a Phase 1/2 study of 55 patients from 4 months to 76 years old with TRK-fusion positive tumors given NTRK inhibitor Larotrectinib. Patients had 17 unique NTRK fusion types. Patient overall re… (full text at CIViC)

PMID 29466156 · Drilon et al., 2018 · Open in CIViC

In this phase 1/2 study 55 patients from 4 months to 76 years old with TRK-fusion positive tumors were given NTRK inhibitor larotrectinib. Patients had 17 unique NTRK fusion types. Patient overall res… (full text at CIViC)

PMID 29466156 · Drilon et al., 2018 · Open in CIViC

In this phase 1/2 study 55 patients from 4 months to 76 years old with TRK-fusion positive tumors were given NTRK inhibitor larotrectinib. Patients had 17 unique NTRK fusion types. Patient overall res… (full text at CIViC)

PMID 29466156 · Drilon et al., 2018 · Open in CIViC

In this phase 1/2 study 55 patients from 4 months to 76 years old with TRK-fusion positive tumors were given NTRK inhibitor larotrectinib. Patients had 17 unique NTRK fusion types. Patient overall res… (full text at CIViC)

PMID 29466156 · Drilon et al., 2018 · Open in CIViC

In the STARTRK-NG (NCT02650401) phase 1/2 trial, 43 pediatric and young adult patients (age <22 years) with recurrent or refractory solid tumors, including primary CNS tumors, were evaluated for respo… (full text at CIViC)

PMID 35395680 · Desai et al., 2022 · Open in CIViC

54 patients aged 18 or older with metastatic or locally advanced NTRK-fusion positive solid tumours (including ten tumour types and 19 unique histologies) were enrolled in one of three phase 1 or 2 tr… (full text at CIViC)

PMID 31838007 · Doebele et al., 2020 · Open in CIViC

A pooled analysis of three phase 1/2 clinical trials investigating the efficacy and safety of larotrectinib in 159 NTRK fusion positive solid tumor patients (1 month - 84 years old) confirmed larotrec… (full text at CIViC)

PMID 32105622 · Hong et al., 2020 · Open in CIViC

Describes a meta-analysis of three separate phase I or II trials: ALKA-372-001, STARTRK-1, and STARTRK-2. All of these evaluate entrectinib in NTRK fusion-positive solid tumours. 31/54 had objective r… (full text at CIViC)

PMID 31838007 · Doebele et al., 2020 · Open in CIViC

This was a Phase 1/2 study of 55 patients from 4 months to 76 years old with TRK-fusion positive tumors given NTRK inhibitor Larotrectinib. Patients had 17 unique NTRK fusion types. Patient overall re… (full text at CIViC)

PMID 29466156 · Drilon et al., 2018 · Open in CIViC

In this phase 1/2 study 55 patients from 4 months to 76 years old with TRK-fusion positive tumors were given NTRK inhibitor larotrectinib. Patients had 17 unique NTRK fusion types. Patient overall res… (full text at CIViC)

PMID 29466156 · Drilon et al., 2018 · Open in CIViC

In this phase 1/2 study 55 patients from 4 months to 76 years old with TRK-fusion positive tumors were given NTRK inhibitor larotrectinib. Patients had 17 unique NTRK fusion types. Patient overall res… (full text at CIViC)

PMID 29466156 · Drilon et al., 2018 · Open in CIViC

In the phase 1/2 clinical trial NCT03037385, one arm assessed the therapeutic benefit of the selective RET inhibitor pralsetinib across a range RET fusion positive solid tumors, excluding NSCLC and th… (full text at CIViC)

PMID 35962206 · Subbiah et al., 2022 · Open in CIViC

In this arm of the trial (LIBRETTO-001), the efficacy of selpercatinib was tested in 45 patients harbouring RET fusion-positive solid tumours (excluding lung or thyroid tumours). The objective respons… (full text at CIViC)

PMID 36108661 · Subbiah et al., 2022 · Open in CIViC

In the phase 1/2 trial LIBRETTO-121 (NCT03899792), for patients 0.5-21 yrs old with advanced RET-altered solid tumors, dosing started at 92 mg/m2 twice a day of Selpercatinib. Patients had RET-mutant… (full text at CIViC)

Open in CIViC

As part of this trial, 27 pediatric patients (aged 2-20), harbouring, RET-mutant medullary thyroid cancer (MTC, n = 14), RET fusion-positive papillary thyroid cancer (RTC, n=10), or other tumour types… (full text at CIViC)

Open in CIViC